{{Rsnum
|rsid=10486275
|Chromosome=7
|position=8963946
|Orientation=plus
|GMAF=0.2309
|Assembly=GRCh38
|GenomeBuild=38.1
|dbSNPBuild=141
|geno1=(C;C)
|geno2=(C;T)
|geno3=(T;T)
}}{{ population diversity
| geno1=(C;C)
| geno2=(C;T)
| geno3=(T;T)
| CEU | 19.5 | 46.0 | 34.5
| HCB | 4.4 | 27.2 | 68.4
| JPT | 3.5 | 38.1 | 58.4
| YRI | 0.0 | 0.0 | 100.0
| ASW | 0.0 | 21.1 | 78.9
| CHB | 4.4 | 27.2 | 68.4
| CHD | 2.8 | 34.3 | 63.0
| GIH | 5.0 | 29.7 | 65.3
| LWK | 0.0 | 0.9 | 99.1
| MEX | 5.2 | 39.7 | 55.2
| MKK | 0.0 | 12.3 | 87.7
| TSI | 8.8 | 53.9 | 37.3
| HapMapRevision=28
}}{{PharmGKB
|RSID=rs10486275
|Name_s=
|Gene_s=-
|Feature=
|Evidence=PubMed ID:19176441
|Annotation=This variant is associated with end-of-induction minimal residual disease (MRD) in childhood acute lymphoblastic leukemia (ALL) from 2 independent cohorts (GWAS result). Risk Allele: T, MAF= 0.32, combined P value= 2.13E-04.
|Drugs=
|Drug Classes=
|Diseases=Neoplasm, Residual; Precursor Cell Lymphoblastic Leukemia-Lymphoma
|Curation Level=Curated
|PharmGKB Accession ID=PA162470210
}}

{{GET Evidence
|impact=pharmacogenetic
|qualified_impact=Insufficiently evaluated pharmacogenetic
|inheritance=unknown
|quality_scores=Array
|dbsnp_id=rs10486275
|overall_frequency_n=33
|overall_frequency_d=128
|overall_frequency=0.257812
|n_genomes=23
|n_genomes_annotated=0
|n_haplomes=27
|n_articles=1
|n_articles_annotated=0
|in_pharmgkb=Y
|autoscore=1
|webscore=N
}}

{{on chip | 23andMe v1}}
{{on chip | 23andMe v2}}
{{on chip | 23andMe v3}}
{{on chip | 23andMe v4}}
{{on chip | Illumina Human 1M}}